NCT05077800 - FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

July 31, 2026

Conditions

Pancreatic AdenocarcinomaPancreatic Adenocarcinoma Metastatic

Interventions

DRUG

FOLFIRNINOX

Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion

DRUG

Losartan

Taken Orally

DRUG

9-ING-41

Administered by intravenous infusion

Trial Locations (3)

Univesity of Colorado, Aurora

University of Washington, Seattle

Massachusetts General Hospital Cancer Center, Boston